Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia.
Ghrelin is a novel growth hormone (GH)-releasing peptide, isolated from the stomach, which has been identified as an endogenous ligand for GH secretagogue receptor. The discovery of ghrelin indicates that the release of GH from the pituitary might be regulated not only by hypothalamic GH-releasing hormone, but also by ghrelin derived from the stomach. This peptide also stimulates food intake and induces adiposity through GH-independent mechanisms. In addition, ghrelin acts directly on the central nervous system to decrease sympathetic nerve activity. Thus, ghrelin plays important roles for maintaining GH release and energy homeostasis. Repeated administration of ghrelin improves body composition, muscle wasting, functional capacity, and sympathetic augmentation in cachectic patients with heart failure or chronic obstructive pulmonary disease. These results suggest that ghrelin has anti-cachectic effects through GH-dependent and independent mechanisms. Thus, administration of ghrelin may be a new therapeutic strategy for the treatment of cardiopulmonary-associated cachexia.
Nagaya
Noritoshi
N
Department of Regenerative Medicine and Tissue Engineering, National Cardiovascular Center Research Institute, Osaka.
Kojima
Masakazu
M
Kangawa
Kenji
K
D000818:Animals; D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology; D005753:Gastric Mucosa / Q000378:metabolism; D054439:Ghrelin; D013006:Growth Hormone / Q000627:therapeutic use*; D006333:Heart Failure / Q000150:complications* / Q000503:physiopathology; D006801:Humans; D036361:Peptide Hormones / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications* / Q000503:physiopathology
D054439:Ghrelin; D036361:Peptide Hormones; D013006:Growth Hormone